BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, €œIkena,€ €œCompany€), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, œIkena, œCompany), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy...
Ikena Oncology is going all in on its two lead assets. After missing out on $90 million from Bristol Myers Squibb, the biotech has outlined plans to lay off 35% of its workforce and shift resources from drug discovery to clinical development of its two top cancer prospects.
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core...
Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment...
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, œIkena, œCompany), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, œIkena, œCompany), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by...